Back to search results

Biologically-Adapted, Dose-Escalated Radiotherapy for Ewing Sarcoma (BEAR Trial)

This study, called the BEAR Trial, is looking at a new way to give radiation therapy for Ewing sarcoma. It tests if adjusting the radiation dose based on your tumor's size and other specific features (biologically-adapted) can work better than standard radiation. Radiation therapy uses high-energy X-rays or particles to kill cancer cells. You would receive chemotherapy, radiation, and possibly surgery. Doctors will measure if this approach reduces the chance of the cancer coming back in the treated area for patients with larger tumors, looking at results for up to two years. This study is for people aged 2 years and older with Ewing sarcoma. The current status of this study is unclear.

Study design
This is an interventional study planning to enroll 141 participants. The specific phase of the study is not mentioned.
What's involved
You would undergo blood sample collection, receive chemotherapy, have CT or PET/CT scans, receive conventional radiotherapy, and potentially undergo definitive surgical resection.
Compensation
Not stated in the trial record.
Follow-up
The primary goal is measured up to 2 years after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07188532

Biologically-Adapted, Dose-Escalated Radiotherapy for the Treatment of Ewing Sarcoma, BEAR Trial

Recruiting
NAAges 2+InterventionalTreatment
Mayo Clinic
~141 participants
Updated 2026-06-04 on ClinicalTrials.gov
What's tested:Biospecimen CollectionChemotherapyComputed TomographyConventional RadiotherapyDefinitive Surgical ResectionDose-escalated Radiation Therapy

At a glance

Recruiting sites
1 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Reduction in local failure for patients with large tumors (Cohort A)
Measured over Up to 2 years

Conditions

Ewing Sarcoma
Round Cell Sarcoma With EWSR1-non-ETS Fusion

Explore related trials

Ewing SarcomaRound Cell Sarcoma with EWSR1-non-ETS FusionEWSR1 Gene

Where it's being run

2 sites across 2 states
Arizona1
Minnesota1

Study leadership

  • Roman O. Kowalchuk, MD · PRINCIPAL_INVESTIGATOR · Mayo Clinic in Rochester

Who to contact

Clinical Trials Referral Office
[email protected]
855-776-0015
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Histological confirmation of Ewing sarcoma, including both skeletal and extra-skeletal primary tumors. Patients with "Ewing-like" sarcoma may be eligible if patients are planned to be treated per Ewing treatment paradigms, as defined in this clinical trial
Patients of age ≥ 2 years are eligible for the study
Lansky or Karnofsky performance status ≥ 70
Ability to provide written informed consent and complete questionnaire(s) by themselves or with assistance
Willing to provide blood samples for correlative research purposes
Willing to provide biopsy sample to run Mayo Complete Solid Tumor Panel if tumor size is \>= 8 cm

Exclusion

Prior chemotherapy or radiotherapy that, in the opinion of the treating medical oncologist or radiation oncologist, is considered to interfere with the current treatment or measurement of outcomes
Receiving any investigational agent which would be considered as a treatment for the primary neoplasm that is considered by the investigator to interfere with the current treatment or measurement of outcomes
Note: Co-enrollment on another clinical trial is allowed per the treating radiation oncologist's discretion
Other active malignancy ≤ 1 year prior to registration that is considered by the investigator to interfere with the current treatment or measurement of outcomes
Patients that have severe co-morbid systemic illness or other disease which would interfere significantly with the current treatment or measurement of outcomes
Patients that have active uncontrolled systemic infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, or psychiatric illness or social situation that would limit study adherence
Any of the following:
Pregnant patients
Nursing patients

What this trial measures

  • Reduction in local failure for patients with large tumors (Cohort A)Up to 2 years

    Large tumors defined as ≥ 8cm. Will be compared to the historical control of 14.3%. Local failure will be defined per the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.